Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Sarepta Therapeutics, Inc.

NASDAQ: SRPT · Life Sciences · 3 alerts · CIK 873303

Share price
$15.13Close, Nov 16
Market cap
$1.62B
Shares outstanding
107.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sarepta Therapeutics, Inc. filings on SEC EDGAR ↗

4:14 PM ET 8-K
Financial Results

Sarepta Therapeutics Financial Results

Sarepta Therapeutics reported Q3 2026 financial results with net product revenues of $323.8 million, driven by its PMO franchise and ELEVIDYS. The company achieved positive cash flow and non-GAAP operating income of $22.9 million while preparing for Phase 3 development in its DM1 and FSHD programs.

Term
Q3 2026

“After my first 90 days at Sarepta, I believe the fundamental strengths that attracted me to the company remain firmly intact: a durable Duchenne franchise, a promising pipeline with the potential to deliver differentiated medicines, and the financial strength to invest in our highest-value opportunities.”

Michael Severino, M.D., chief executive officer, Sarepta

“This quarter, we saw continued strength in our commercial execution. Our upcoming DM1 and FSHD datasets are important opportunities to demonstrate the depth of knockdown and downstream biological effects we believe our platform can achieve.”

Michael Severino, M.D., chief executive officer, Sarepta
4:02 PM ET 10-Q
Financial Results

Sarepta Therapeutics Q3 2026 Results: Net Loss of $28.5M, Loss Narrows

Sarepta Therapeutics reported a net income of $297.6 million for the first nine months of 2026, a significant turnaround from a $301.2 million loss in the prior year period. Total revenues for the nine months reached $1.51 billion, driven by $983.0 million in net product sales and $530.4 million from collaboration and other revenue.

Key figure
Net loss $28.5M
4:14 PM ET 8-K
Court & Legal Update

Sarepta Therapeutics Court & Legal Update

Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, the University of Pennsylvania, and Catalent to resolve pending patent infringement litigation regarding the '274 and '617 patents. Sarepta will pay a lump sum of $39.0 million to REGENXBIO in exchange for a release of claims and a covenant not to sue regarding Sarepta's gene therapy products using the AAVrh74-based capsid, including ELEVIDYS. The settlement resolves all pending litigations with prejudice and includes no admission of liability.

Counterparty
REGENXBIO Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.